Spectral AI to Participate in Benchmark’s 12th Annual Discovery One-on-One Conference
30 November 2023 - 10:10PM
Spectral AI, Inc.
(Nasdaq: MDAI; MDAIW) (“Spectral AI” or the
“Company”), an artificial intelligence (AI) company
focused on medical diagnostics for faster and more accurate
treatment decisions in clinical wound care, today announced that it
will participate in the Benchmark 12th Annual Discovery One-on-One
Conference being held on December 7, 2023 in New York City.
Management will participate in 1x1 meetings
throughout the day with institutional investors. For more
information on the Benchmark 12th Annual Discovery One-on-One
Conference, or to schedule a one-on-one meeting, please contact
your Benchmark representative or visit the Conference Website:
Click here.
Spectral AI Company
Highlights
- Spectral AI’s
DeepView® System provides clinicians with an objective and
immediate assessment of a wound’s healing potential through the
application of proprietary AI algorithms, with initial applications
involving patients with burns and diabetic foot ulcers (DFU).
- In September
2023, Spectral AI received the largest contract in its history from
the U.S. Government valued at up to $149 million to support the
clinical validation and FDA clearance of the DeepView® System for
burn wound assessment. Together with previous contracts, this
brings total U.S. Government awards to the Company since
2019 to more than $246.0 million.
- Multiple
clinical studies have validated the efficacy of the DeepView®
System in assessing - within seconds - whether a burn wound or DFU
will heal on its own or will require medical intervention to do
so.
- The Company
expects to submit applications for FDA, UKCA, and CE mark approval
for the DeepView® System DFU indication and 3D wound measurement in
2024, and for FDA and CE mark approval for the burn indication in
2025.
About Spectral AISpectral AI,
Inc. is a Dallas-based predictive AI company focused on medical
diagnostics for faster and more accurate treatment decisions in
wound care, with initial applications involving patients with burns
and diabetic foot ulcers. The Company is working to revolutionize
the management of wound care by “Seeing the Unknown®” with its
DeepView® System. DeepView® is a predictive diagnostic
device that offers clinicians an objective and immediate assessment
of a wound’s healing potential prior to treatment or other medical
intervention. With algorithm-driven results and a goal of
substantially exceeding the current standard of care in the future,
DeepView® is expected to provide faster and more accurate
treatment insight towards value care by improving patient outcomes
and reducing healthcare costs. For more information about
DeepView®, visit www.spectral-ai.com.
Forward Looking
StatementsCertain statements made in this release are
“forward looking statements” within the meaning of the “safe
harbor” provisions of the United States Private Securities
Litigation Reform Act of 1995, including statements regarding the
Company’s strategy, plans, objectives, initiatives and financial
outlook. When used in this press release, the words “estimates,”
“projected,” “expects,” “anticipates,” “forecasts,” “plans,”
“intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,”
“propose” and variations of these words or similar expressions (or
the negative versions of such words or expressions) are intended to
identify forward-looking statements.
These forward-looking statements are not
guarantees of future performance, conditions or results, and
involve a number of known and unknown risks, uncertainties,
assumptions and other important factors, many of which are outside
Company’s control, that could cause actual results or outcomes to
differ materially from those discussed in the forward-looking
statements. As such, readers are cautioned not to place undue
reliance on any forward-looking statements.
Investors should carefully consider the
foregoing factors and the other risks and uncertainties described
in the “Risk Factors” sections of the Company’s filings with the
SEC, including the Registration Statement and the other documents
filed by the Company. These filings identify and address other
important risks and uncertainties that could cause actual events
and results to differ materially from those contained in the
forward-looking statements.
Contacts: |
|
Investors: |
|
Spectral AI |
The Equity Group |
Vince Capone |
Devin Sullivan, Managing Director |
General Counsel |
dsullivan@equityny.com |
ir@spectral-ai.com |
|
|
Conor Rodriguez, Analyst |
|
crodriguez@equityny.com |
Media: |
|
Russo Partners |
|
David Schull |
Guillermo Ruiz, M.D., Ph.D. |
Russo Partners |
Russo Partners |
(858) 717-2310 |
(646) 218-4604 |
david.schull@russopartnersllc.com |
guillermo.ruiz@russopartnersllc.com |
Spectral AI (NASDAQ:MDAI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Spectral AI (NASDAQ:MDAI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024